Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593 on ClinicalTrials.gov · last registry update 2026-08-21
An unusually large phase 3: 1,205 participants, more than double the 424 typical for the stage. Due to report June 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in Maximum Walking Distance. Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- RECRUITING
- Phase
- P3
- Drug
- orforglipronFoundayo
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 1,205
- Started
- 2025-10-31
- Primary completion
- 2028-06 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Change from Baseline in Maximum Walking Distance
Conditions studied
Peripheral Arterial Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.